Control of Cholesterol Metabolism --Bile Acid Transport

胆固醇代谢的控制——胆汁酸转运

• 批准号: 7225967
• 负责人: John M. Dietschy
• 金额: $ 80.15万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1965
• 资助国家: 美国
• 起止时间: 1965-06-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7225967
• 关键词: ATP binding cassette transporter 1; Acute; Alzheimer' s Disease; Animals; Apolipoprotein E; Apoptosis; Area; Atherosclerosis; Behavior; Bile Acid Biosynthesis Pathway; Bile Acids; Biochemistry; Blood - brain barrier anatomy; Brain; CYP46A1 gene; Cell Death; Cell membrane; Cells; Cessation of life; Child; Cholesterol; Cholesterol Homeostasis; Cirrhosis; Clinical; Clinical Medicine; Condition; Coronary Arteriosclerosis; Coronary Occlusions; Data; Defect; Dementia; Development; Disease; Enterohepatic Circulation; Epithelial Cells; Equilibrium; Event; Excretory function; Extrahepatic; Gangliosides; Gene Targeting; Goals; Grant; Hepatic; Hepatocyte; Hydroxylation; Icterus; Inflammation; Intestines; Investigation; Kinetics; Knockout Mice; LDL Cholesterol Lipoproteins; Lead; Liver; Liver Failure; Liver diseases; Lysosomes; Measures; Metabolism; Mixed Function Oxygenases; Modeling; Molecular; Movement; Mus; Mutation; Natural History; Nerve Degeneration; Nervous System Physiology; Neuraxis; Neurologic; Neurologic Dysfunctions; Neurons; Nuclear Receptors; Organ; Pathway interactions; Perinatal; Personal Satisfaction; Pharmacologic Substance; Physiological; Plasma; Play; Prevention; Process; Proteins; Rate; Regulation; Research Personnel; Role; Site; Sterols; Supraoptic Vertical Ophthalmoplegia; Testing; Tissues; Ursidae Family; brain size; cholesterol 24-hydroxylase; cholesterol transporters; genetic regulatory protein; knockout animal; mouse model; numb protein; prevent; programs; research study; sterol O-acyltransferase 2; vitamin D3 25-hydroxylase

DESCRIPTION (provided by the applicant): The broad objective of these studies is to further understand the processes that regulate cholesterol movement across plasma membranes and across the blood brain barrier of the central nervous system. These studies have direct relevance to two broad areas of clinical medicine: the mechanisms of neurodegeneration and dementia and the formation of atherosclerosis. In general, all of these studies will be undertaken using a variety of knockout mice that lack one or more critical proteins for sterol movement. Absolute rates of cholesterol flux across the plasma membranes of various tissues or across the blood brain barrier will be measured and neurological and hepatic function will be assessed. The first set of experiments will investigate the possible role of apoE, ABCA1, SR-BI and LDLR in the movement of cholesterol between the CMS and the plasma. A second set of experiments will test the hypothesis that cholesterol and ganglioside accumulation leads to neurodegeneration in mice with a mutation in NPC1. A third set of studies will explore various agents that might alter the rate of neuron death in the brain and ameliorate the neurological dysfunction seen in Niemann-Pick type C disease. Mice (and children) with NPC disease also develop serious liver abnormalities. A fourth group of studies will explore new pharmaceutical agents that interrupt the enterohepatic circulation of cholesterol and might prevent such liver cell death. The protein ABCA1 is expressed ubiquitously in every organ, including the central nervous system but its exact function in promoting cholesterol transport is unknown. In a fifth set of studies, absolute cholesterol flux rates will be measured in every organ under conditions where this protein is either deleted or over expressed. A sixth set of studies will examine the relationship between NPC1L1, ACAT-2 and ABCA1 in regulating cholesterol flow through the enterohepatic circulation and, hence, the level of LDL-C. Finally, studies are also planned to explore the molecular regulation of the alternative pathway for bile acid synthesis that is initiated by sterol 27-hydroxylase. With the information gained from these studies, it is possible that new therapies can be developed to prevent neurodegeneration with dementias such as Alzheimer's disease, and to prevent atherosclerosis and diseases such as acute coronary occlusion.

描述(由申请人提供)：这些研究的广泛目标是进一步了解调节胆固醇跨膜和跨中枢神经系统血脑屏障移动的过程。这些研究与临床医学的两个广泛领域直接相关：神经退行性变和痴呆的机制以及动脉粥样硬化的形成。总体而言，所有这些研究都将使用各种基因敲除小鼠进行，这些小鼠缺乏一种或多种类固醇运动的关键蛋白质。将测量跨不同组织质膜或跨血脑屏障的胆固醇流量的绝对速率，并将评估神经和肝脏功能。第一组实验将研究载脂蛋白E、ABCA1、SR-BI和LDLR在CMS和血浆之间胆固醇转移中的可能作用。第二组实验将检验这一假设，即胆固醇和神经节苷脂的积累会导致NPC1突变小鼠的神经退化。第三组研究将探索可能改变大脑中神经元死亡率并改善尼曼-皮克C型疾病所见的神经功能障碍的各种因素。患有鼻咽癌疾病的小鼠(和儿童)也会出现严重的肝脏异常。第四组研究将探索新的药物制剂，这些药物可以阻断胆固醇的肠-肝循环，并可能防止这种肝细胞死亡。ABCA1蛋白在包括中枢神经系统在内的各个器官中普遍表达，但它在促进胆固醇运输方面的确切功能尚不清楚。在第五组研究中，将在这种蛋白质缺失或过度表达的条件下测量每个器官的绝对胆固醇流量。第六组研究将考察NPC1L1、ACAT-2和ABCA1在调节通过肠-肝循环的胆固醇流动中的关系，从而调节低密度脂蛋白-C水平。最后，研究还计划探索由甾醇27-羟基酶启动的胆汁酸合成替代途径的分子调控。根据这些研究获得的信息，有可能开发新的疗法来预防阿尔茨海默病等痴呆症的神经退化，并预防动脉粥样硬化和急性冠状动脉闭塞等疾病。